Serum glucose was estimated Venetoclax by Oxidase method.17 The activities of serum AST and ALT were assayed by Reitman and Frankel method.18 Total cholesterol19 and triglycerides20 were determined by the respective method. Liver was dissected out and washed in normal saline and stored −80 °C for assay of glycogen content by using Anthrone reagent.21 Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by student’s‘t’ test. The values are mean ± SD for six rats in each group. Statistical significance was considered at

p < 0.05. There was a significant elevation of serum glucose, total cholesterol, triglycerides, aspartate transaminase, alanine transaminase while liver glycogen significantly decreased in the diabetic control rats as compared with non-diabetic control group. Table 1 showed the blood glucose levels of the control, Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) at different time points (0, 30, 60, 120, 150 min) after oral administration of glucose (2 g/kg). There was a peak increase in the blood glucose at 30 min in all the groups. In Glibenclamide and 400 mg of MEDH treated group, there was a decrease in blood glucose level at 150 min when compared to control group. Table 2 showed the level of blood GDC-0449 mw glucose in euglycemic rats at 0, 1, 2 and 4 h of administration. The administration of Glibenclamide (7 mg/kg)

and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) on euglycemic rats was not significant at

1 h, while it was significant at 4 h (p < 0.05) as compared to control. The level of blood glucose in normal and diabetic rats at 0, 1, 2 and 4 h of administration was showed in Table 3. There was a significant elevation of blood glucose level in diabetic group as compared to normal control rats. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) reduced the blood glucose in diabetic rats as compared to control rats. The 4th day treatment with Glibenclamide and 400 mg of MEDH resulted in significant hypoglycemic effect in diabetic group. Table 4 showed the level of serum AST and ALT and liver glycogen in normal and experimental rats. There was a Terminal deoxynucleotidyl transferase significant elevation of serum AST and ALT and decrease in liver glycogen content in diabetic control as compared to non-diabetic control rats. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) significantly decreased AST and ALT levels and increased glycogen content in diabetic rats as compared to control rats. There was a significant increase in the cholesterol and triglycerides in diabetic rats as compared to control. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) brought back the levels of cholesterol and triglycerides to near normal rats ( Table 5).